11.19.2025
Therapeutics
$2,498,429.00
36 months
The SYMPTOM Trials: Scalable, community-based methods for persistent IBS-like symptoms in Crohn's Disease in remission.
This randomized, placebo-controlled clinical trial aims to demonstrate the safety and efficacy of tricyclic antidepressants (TCAs) for Crohn's disease patients who have persistent gastrointestinal symptoms despite controlled inflammation. Results from this study will inform the incorporation of TCAs into clinical practice to improve patient quality of life.